Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reparixin - Dompe Farmaceutici

Drug Profile

Reparixin - Dompe Farmaceutici

Alternative Names: DF-1681Y; Repertaxin; Repertaxin L-Lysine salt

Latest Information Update: 21 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dompe Farmaceutici
  • Developer Dompe Farmaceutici; Fox Chase Cancer Center; SatRx; University of Michigan Comprehensive Cancer Center
  • Class Antineoplastics; Benzeneacetamides; Small molecules; Sulfonamides
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Delayed graft function
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Delayed graft function
  • Phase II Breast cancer; Liver transplant rejection
  • Discontinued Cerebral ischaemia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Jan 2018 Dompe Farmaceutici completes a phase II/III trial in Delayed graft function (Prevention) in Canada, USA (IV) (NCT01967888)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top